Valuation: International Stem Cell Corporation

Market Cap 2.32M 2.06M 1.92M 1.75M 3.31M 223M 3.34M 23.3M 9.03M 114M 8.72M 8.53M 366M P/E 2024
-3.11x
P/E 2025 -2.68x
Enterprise Value 5.06M 4.5M 4.2M 3.83M 7.21M 487M 7.28M 50.79M 19.68M 249M 19M 18.59M 798M EV / Sales 2024
0.36x
EV / Sales 2025 0.42x
Free-Float
29.26%
Yield 2024 *
-
Yield 2025 -
08-31 American Type Culture Collection Inc. completed the acquisition of Lifeline Cell Technology, LLC from International Stem Cell Corporation for $25.2 million. CI
08-13 International Stem Cell Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 CI
07-23 American Type Culture Collection Inc. entered into Membership Interest Purchase Agreement to acquire Lifeline Cell Technology, LLC from International Stem Cell Corporation for $25 million. CI
05-14 International Stem Cell Corporation Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
03-30 International Stem Cell Corporation Reports Earnings Results for the Full Year Ended December 31, 2025 CI
03-29 International Stem Cell Corporation Auditor Raises 'Going Concern' Doubt CI
11-13 International Stem Cell Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 CI
25-09-16 International Stem Cell Corporation Announces Extension of Loan Maturity with Detailed Terms on Principal and Interest CI
25-08-14 International Stem Cell Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025 CI
25-05-14 International Stem Cell Corporation Reports Earnings Results for the First Quarter Ended March 31, 2025 CI
25-03-28 International Stem Cell Corporation Reports Earnings Results for the Full Year Ended December 31, 2024 CI
25-03-27 International Stem Cell Corporation Auditor Raises 'Going Concern' Doubt CI
24-11-13 International Stem Cell Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 CI
1 day-3.01%
1 week-16.08%
Current month-6.45%
1 month-30.95%
3 months+45.00%
6 months+70.59%
Current year+107.14%
1 week 0.29
Extreme 0.29
0.33
1 month 0.28
Extreme 0.28
0.53
Current year 0.12
Extreme 0.117
0.54
1 year 0.12
Extreme 0.117
0.54
3 years 0.05
Extreme 0.046
0.54
5 years 0.05
Extreme 0.046
0.54
10 years 0
Extreme 0
2.5
Manager TitleAgeSince
Chief Executive Officer 66 2009-10-31
Chief Tech/Sci/R&D Officer 40 2013-05-31
Director TitleAgeSince
Director/Board Member 40 2008-09-30
Chairman 66 2008-11-30
Director/Board Member 78 2007-06-30
Date Insider Type Main position Quantity % Market Cap. Importance
9/16/26 Issuer sale

Director

-30,000 0.3748%
9/11/26 Sell

Director

-32,802 0.4098%
6/11/26 Free

Director

212,584 2.6558%
Change 5-day change 1-year change 3-year change Capi.($)
-3.01%-16.08%+123.08%+139.67% 2.32M
+4.16%+3.04%+49.37%+94.17% 74.16B
-3.11%-3.53%+20.19%+81.44% 57.39B
+0.89%-0.63%+2.17%+36.19% 47.64B
+0.36%+0.81%+342.39%+742.40% 44.29B
-0.96%-4.50%+24.96%+35.38% 42.5B
-0.20%-0.77%+4.13%+105.50% 40.71B
-0.54%+2.93%+9.31%+50.41% 30.97B
-2.68%+2.92%+29.33%+22.72% 28.53B
+0.05%-1.64%-8.14%-11.37% 24.34B
Average -0.50%-0.53%+59.68%+129.65% 39.05B
Weighted average by Cap. +0.12%-0.84%+56.96%+138.26%

Financials

2024 2025
Net sales 9.08M 8.07M 7.53M 6.87M 12.95M 873M 13.07M 91.17M 35.33M 446M 34.11M 33.37M 1.43B 9.1M 8.09M 7.55M 6.88M 12.97M 875M 13.09M 91.32M 35.39M 447M 34.17M 33.42M 1.44B
Net income -209K -186K -173K -158K -298K -20.09M -301K -2.1M -813K -10.27M -785K -768K -32.96M -418K -371K -347K -316K -596K -40.18M -601K -4.19M -1.63M -20.54M -1.57M -1.54M -65.93M
Net Debt 2.61M 2.32M 2.16M 1.97M 3.72M 251M 3.76M 26.19M 10.15M 128M 9.8M 9.59M 412M 2.74M 2.43M 2.27M 2.07M 3.91M 263M 3.94M 27.5M 10.66M 135M 10.29M 10.06M 432M
Logo International Stem Cell Corporation
International Stem Cell Corporation is a clinical-stage biotechnology company that is focused on therapeutic and biomedical product development. The Company is primarily a research and development company for the therapeutic market, which has focused on advancing potential clinical applications of human parthenogenetic stem cells (hpSCs) for the treatment of various diseases of the central nervous system and liver diseases. The Company's products are based on human cell culture and types of pluripotent stem cells and hpSCs. The Company's subsidiaries include Lifeline Cell Technology, LLC (LCT), which develops, manufactures and commercializes primary human cell research products for the biomedical market; Lifeline Skin Care, Inc. (LSC), which develops, manufactures and markets a category of anti-aging skin care products for anti-aging market, and Cyto Therapeutics Pty. Ltd. (Cyto Therapeutics) performs research and development (R&D) for the therapeutic market.
Employees
33
Date Price Change Volume
26-10-02 US$0.2900 -3.01% 1,034
26-10-01 US$0.2990 -3.55% 9,151
26-09-30 US$0.3100 -6.06% 338
26-09-29 US$0.3300 +1.54% 3,144
26-09-28 US$0.3250 -5.95% 120
  1. Stock Market
  2. Stocks
  3. ISCO Stock